目的 探討兒童清肺口服液聯(lián)合環(huán)酯紅霉素治療兒童肺炎支原體肺炎的臨床療效。方法 選取2021年12月—2023年12月北京市通州區(qū)婦幼保健院收治的124例肺炎支原體肺炎患兒，按隨機數(shù)字表法將患者分為對照組和治療組，每組各62例。對照組予以環(huán)酯紅霉素干混懸劑，15 mg/kg，加入適量涼開水沖調，搖勻后使用，每間隔12 h用藥1次。治療組在此基礎上口服兒童清肺口服液，3次/d，其中1歲≤年齡≤6歲者1支/次，年齡>6歲者2支/次。兩組療程均為7 d。觀察兩組臨床療效，主要臨床表現(xiàn)消失時間，比較兩組治療前后臨床肺部感染評分（CPIS）、肺炎胸片吸收評價量表評分（PCRAES）、和外周血血小板與淋巴細胞比值（PLR）、CD3⁺CD56⁺自然殺傷（NK）細胞和血清補體C4、腫瘤壞死因子-α（TNF-α）水平。結果 治療后，治療組總有效率是95.16%，顯著高于對照組的83.87%（P<0.05）。治療后，治療組退熱時間和咳嗽、痰壅、氣喘、肺部啰音消失時間顯著短于對照組（P<0.05）。治療后，兩組CPIS、PCRAES評分都低于治療前（P<0.05）；治療后，治療組CPIS、PCRAES評分都低于對照組（P<0.05）。治療后，兩組外周血PLR、CD3⁺CD56⁺NK細胞和血清補體C4、TNF-α水平都低于治療前（P<0.05）；治療后，治療組這些指標低于對照組（P<0.05）。結論 兒童清肺口服液聯(lián)合環(huán)酯紅霉素治療兒童肺炎支原體肺炎可有效加快患兒癥狀減輕，促進肺部感染和機體炎癥控制，安全性較高，穩(wěn)定病情效果較好，值得臨床推廣應用。

Objective To explore the clinical efficacy of Ertong Qingfei Oral Liquid combined with erythromycin cyclocarbonate in treatment of mycoplasma pneumoniae in children.Methods A total of 124 children with mycoplasma pneumonia admitted to Beijing Tongzhou Maternal and Child Health Hospital from December 2021 to December 2023 were selected and divided into control group and treatment group according to random number table method,with 62 cases in each group.Children in control group were given Erythromycin Cyclocarbonate for Suspension,15 mg/kg,added appropriate amount of cold water to rinse,shaked well,once every 12 h.Children in treatment group were po administered with Ertong Qingfei Oral Liquid on the basis of control group,3 times daily,1 year≤children≤6 years,1 piece/time,children＞6 years,2 pieces/time.Children in two groups were treated for 7 d.After treatment,the clinical efficacy,main clinical manifestations disappeared time were observed.The levels of CPIS score,PCRAES score,PLR,CD3⁺CD56⁺NK cells,serum complement C4,and TNF-α in two groups before and after treatment were compared.Results After treatment,the total effective rate of treatment group was 95.16%,which was significantly higher than that of control group （83.87%）（P＜0.05）.After treatment,the time of fever remission and disappearance of cough,phlegm obstruction,asthma and pulmonary rales in the treatment group were significantly shorter than those in control group （P＜0.05）.After treatment,CPIS and PCRAES scores in both groups were lower than those before treatment （P＜0.05）.After treatment,CPIS and PCRAES scores in treatment group were lower than those in control group （P＜0.05）.After treatment,the levels of peripheral blood PLR,CD3⁺CD56⁺NK cells and serum complement C4 and TNF-α in two groups were lower than before treatment （P＜0.05）.After treatment,these indexes in treatment group were lower than those in control group （P＜0.05）.Conclusion Ertong Qingfei Oral liquid combined with erythromycin cyclocarbonate in treatment of mycoplasma pneumoniae in children can effectively accelerate the reduction of symptoms,promote the control of lung infection and body inflammation with high safety and stable disease effect,which is worthy of clinical promotion and application.

R974

北京市通州區(qū)科技計劃項目(KJ2022CX051)